



Global Reporting Frameworks

Pfizer continues to evaluate our approach to non-financial reporting, including adherence to several existing, globally recognized external frameworks.

These include the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the International Integrated Reporting Council (IIRC). We have relied on elements of each framework in developing this year's Annual Review while adhering to none in its entirety. We have included a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources.

We also take into account elements of other Environment, Social and Governance (ESG) indices and sustainability indicators, in particular the Access to Medicines Index and the United Nations (UN) Sustainable Development Goals (SDGs).

GRI reference table

GRI Indicator	Description	Reference	Alignment with the UN SDGs ¹
STRATEGY AND ANALYSIS			
G4-1	CEO / Chair Statement	CEO Letter	
ORGANIZATIONAL PROFILE			
G4-3	Company name	Pfizer Inc.	
G4-4	Company brand, products and services	CEO Letter	
G4-5	Location of headquarters	New York, New York (U.S.)	
G4-6	Main countries of operation	Global Commercial Businesses	
G4-8	Markets served (e.g. sectors, customers)	Our Business	
G4-9	Scale of company (e.g. employees, sales)	CEO Letter	
G4-10	Employee profile	Pfizer Careers	Goal 8
G4-12	Description of company supply chain	Our Business	
G4-14	Precautionary approach / principle	Pfizer manages and reports on our risks and impacts in consideration of the precautionary principle.	
IDENTIFIED MATERIAL ASPECTS AND BOUNDARIES			
G4-17	Entities included in financial statements	About This Review	
G4-18	Process for defining report content	About This Review	
G4-19	Material issues / aspects identified	About This Review	
G4-23	Significant changes in scope / boundaries	Pfizer footprint and capabilities grew with the acquisition of AstraZeneca's anti-infectives portfolio, Bamboo Therapeutics, BIND Therapeutics, and Medivation, Inc. which are included in the 2016 Annual Review .	
STAKEHOLDER ENGAGEMENT			
G4-24	Stakeholders engaged	CEO Letter	
G4-26	Approach to stakeholder engagement	Partnerships	

GRI Indicator	Description	Reference	Alignment with the UN SDGs ¹
REPORT PROFILE			
G4-28	Reporting period	About This Review	
G4-29	Date of previous report	See Previous Annual Review	
G4-30	Reporting cycle	About This Review	
G4-31	Reporting contact point	Chris Gray, Senior Director, Corporate Responsibility	
G4-32	In accordance option chosen	GRI Reference Table	
GOVERNANCE			
G4-34	Governance structure	Governance and Ethics	
G4-37	Governance and stakeholder engagement	Corporate Governance FAQs	Goal 16
G4-38	Composition of the Board	Board of Directors	Goals 5, 16
G4-39	Chair of the Board	Board of Directors	Goal 16
G4-40	Nomination of Board Members	The Pfizer Board: Board Policies	Goal 5, 16
G4-41	Conflict of interest and the Board	The Pfizer Board: Board Policies	Goal 16
ETHICS AND INTEGRITY			
G4-56	Values, principles and codes	Pfizer Compliance	Goal 16
ECONOMIC			
DMA	Disclosures on Management Approach	SDGs	
G4-EC1	Direct economic value	Transforming Delivery of High Quality Products	Goals 2, 5, 7, 8, 9
G4-EC7	Infrastructure investments and services	Bringing Resources to Bear to Improve Global Health	Goals 2, 5, 7, 9, 11
G4-EC9	Local supplier spending	Transforming Delivery of High Quality Products	Goal 12
ENVIRONMENTAL			
DMA	Disclosures on Management Approach	Environment, Health and Safety	
G4-EN8	Total water withdrawal by source	Environment, Health and Safety	Goal 6
G4-EN23	Total waste	Environment, Health and Safety	Goals 3, 6, 12
G4-EN27	Mitigation of product impacts	Environment, Health and Safety	Goals 6, 8, 12, 13, 14, 15
G4-EN33	Supply chain environmental impacts	Environment, Health and Safety	

GRI Indicator	Description	Reference	Alignment with the UN SDGs ¹
SOCIAL: LABOR PRACTICES AND DECENT WORK			
DMA	Disclosures on Management Approach	Culture	
G4-LA6	Injuries and work related fatalities	Culture	Goals 3, 8
G4-LA9	Employee training	Culture	Goals 4, 5, 8
G4-LA10	Employee skills and learning	Culture	Goal 8
SOCIAL: HUMAN RIGHTS			
DMA	Disclosures on Management Approach	Governance and Ethics	
G4-HR2	Human rights training	Human Rights Statement	
G4-HR3	Discrimination	Culture	Goals 5, 8, 16
SOCIAL: SOCIETY			
DMA	Disclosures on Management Approach	Governance and Ethics	
G4-SO1	Local community engagement	Public Health Impact	
G4-SO2	Impacts on local communities	Public Health Impact	Goals 1, 2
G4-SO3	Anti-corruption risk	Practical Ethical Sales and Marketing	Goal 16
G4-SO6	Political contributions	Corporate and Shareholder Information	Goal 16
SOCIAL: PRODUCT RESPONSIBILITY			
DMA	Disclosures on Management Approach	Product Stewardship	
		How We Conduct Clinical Trials	
G4-PR1	Health and safety impacts of products	Manufacturing and Supply Chain	
G4-PR5	Customer satisfaction	Access to Medicines	
G4-PR8	Customer privacy breaches	Clinical Trials	Goal 16

The product information provided in this document is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
© 2017 Pfizer Inc. All rights reserved